We fully appreciate that some trade partners, like Malaysia, may have concerns on the export authorisation system put in place by the EU on 30 January. This is not an export ban, but a mechanism to have transparency over where vaccines made by companies with whom the EU has signed a contract are going.
All vaccines purchased in the context of the COVAX scheme are exempt, including those purchased by self-financing participants such as Malaysia.
Only vaccines purchased outside the COVAX scheme from producers in the European Union for delivery before the end of March 2021 require an export authorisation. The export authorisations will ensure transparency in a sensitive market, and avoid reselling, litigation and trafficking. They will be conducted in a speedy manner to avoid unnecessary delays. It is a transparency and proportionality mechanism. In particular, exports to third countries, including Malaysia, under existing Advance Purchase Agreements (APAs) will be safeguarded to the largest extent feasible.
The EU is mindful of Advanced Purchase Authorisations contracted by Malaysia, and will endeavour to ensure that Malaysia’s expectations to obtain its deliveries will be met. We have made a call on all companies with APAs manufacturing in the EU to honour their obligations to deliver on their commitments.
Ambassador of the European Union Delegation to Malaysia